The efficacy and safety of DOACs and warfarin in pivotal atrial fibrillation randomized controlled trials in Asians
| Study . | Type of DOACs and doses . | Stroke and systemic embolism, n/N (% patient years) . | Major bleeding, n/N (% patient years) . | ||
|---|---|---|---|---|---|
| DOACs . | Warfarin . | DOACs . | Warfarin . | ||
| RELY30 | Dabigatran 150 mg po twice daily | 25/933 (1.4) | 53/926 (3.1) | 39/933 (2.2) | 66/926 (3.8) |
| Dabigatran 110 mg po twice daily | 44/923 (2.5) | 39/923 (2.2) | |||
| ROCKET AF31 | Rivaroxaban 20 mg po once daily | 21/932 (2.6) | 27/464 (3.4) | 23/932 (3.4) | 35/464 (5.1) |
| ARISTOTLE32 | Apixaban 5 mg po twice daily | 44/988 (2.5) | 60/1005 (3.4) | 33/988 (2.0) | 63/1005 (3.8) |
| ENGAGE TIMI33 | Edoxaban 60 mg po once daily | 20/642 (1.3) | 38/641 (2.6) | 42/642 (2.9) | 68/641 (4.8) |
| Edoxaban 30 mg po once daily | 38/652 (2.5) | 24/652 (1.6) | |||
| Study . | Type of DOACs and doses . | Stroke and systemic embolism, n/N (% patient years) . | Major bleeding, n/N (% patient years) . | ||
|---|---|---|---|---|---|
| DOACs . | Warfarin . | DOACs . | Warfarin . | ||
| RELY30 | Dabigatran 150 mg po twice daily | 25/933 (1.4) | 53/926 (3.1) | 39/933 (2.2) | 66/926 (3.8) |
| Dabigatran 110 mg po twice daily | 44/923 (2.5) | 39/923 (2.2) | |||
| ROCKET AF31 | Rivaroxaban 20 mg po once daily | 21/932 (2.6) | 27/464 (3.4) | 23/932 (3.4) | 35/464 (5.1) |
| ARISTOTLE32 | Apixaban 5 mg po twice daily | 44/988 (2.5) | 60/1005 (3.4) | 33/988 (2.0) | 63/1005 (3.8) |
| ENGAGE TIMI33 | Edoxaban 60 mg po once daily | 20/642 (1.3) | 38/641 (2.6) | 42/642 (2.9) | 68/641 (4.8) |
| Edoxaban 30 mg po once daily | 38/652 (2.5) | 24/652 (1.6) | |||
po, per os.